Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

Thallion Pharmaceuticals develops products for the treatment of cancer and infections. Thallion has three leading products in various developmental stages. The Shigamabs drug candidate is targeted to treat Shigatoxin producing E. coli infections. The company's TLN-232 is being evaluated as a treatment of a number of cancer conditions. Its TLN-4601 is another oncology focused treatment. Thallion was considering the possible sale of the company until it received a nearly $9 million capital infusion through an arrangement with Premium Brands. Though Thallion's operations didn't change, and it's still owned by the same shareholders, the move did take the company public.

Alnylam Pharmaceuticals, Inc. company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase II human clinical trial, which is, as of December 31, 2008, ongoing, to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV. As of December 31, 2008, it formed collaborations with Cubist Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd., for the development and commercialization of products for RSV.

Delcath Systems, Inc. was founded in 1988 and is based in New York, New York. Delcath Systems, Inc., a development stage company, develops and manufactures devices to administer high dose chemotherapy and other therapeutic agents directly to diseased organs or regions of the body. It focuses on the development of the Delcath PHP System, a Phase III clinical trial product, which isolates the liver from the patient's general circulatory system and delivers high dose of melphalan hydrochloride or other therapeutic agents directly to the liver. The Delcath PHP System kit includes an arterial infusion catheter, a multi-passageway/double balloon catheter, a blood tubing/extracorporeal filtration circuit, two activated carbon hemoperfusion filters, a return catheter/a thin-walled blood sheath, and a series of introducers and related accessories to properly place the catheters. The company also conducts Phase II clinical trials to test the Delcath PHP System with the drug melphalan against liver cancer/hepatocellular tumors, neuroendocrine and adenocarcinoma tumors that have spread to the liver, and melanomas metastatic to the liver that have received prior regional treatment. It has a collaboration with the National Cancer Institute to develop and evaluate the Delcath PHP System device to deliver high-dose melphalan to patients, and to evaluate the use of additional chemotherapy agents with the Delcath PHP System.

Spectrum Laboratories is wrapped up in a full gamut of filtration products. Spectrum operates three product groups: bioprocessing (membranes, membrane devices, diagnostics, and pharmaceuticals), Original Equipment Manufacturing (or "OEM", which supplies filtration and separation devices to companies making in vivo and ex-vivo filtration devices), and disposable operating room products (orthopedic and arthroscopic drapes, sterile microscope covers, tissue carriers, and other disposables). Spectrum also does contract manufacturing to create customized products with filtration applications for laboratory use. It has three production facilities in the US along with sales offices in the Netherlands and Japan.

Pain Therapeutics, Inc. was founded in 1998 and is based in San Mateo, California. Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and PTI-188 for the treatment of metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and other abuse-resistant opioid painkillers.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

NicOx S.A. company researches nitric oxide-donating drugs for the treatment of cardiovascular and metabolic ailments, inflammation, and pain. NicOx is researching the combination of nitric oxide with various compounds to treat a variety of diseases, including osteoarthritis, atherosclerosis (vascular inflammation), hypertension, ophthalmic conditions, and respiratory diseases. Its drug development efforts are partially conducted through co-development and licensing agreements with larger drug companies.

RegeneRx Biopharmaceuticals was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development include RGN-137, a topically applied gel for chronic dermal wounds; RGN-259, a sterile topical eye drop for ophthalmic wounds; and RGN-352, a parenteral formulation for the treatment of patients with an acute myocardial infarction, or heart attack. Its pre-clinical development product includes RGN-457, an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases. The company has a strategic partnership with Defiante Farmaceutica L.d.a. for the development and marketing of RGN-137, and certain indications relating to RGN-352 primarily in Europe.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.